Inactive Instrument

Inter Pharma Stock OTC Markets

IPTB.F

TH9474010005

Interpharma Public Company Limited is a Thailand-based company that develops, researches and distributes healthcare products and beauty initiatives for human beings, and healthcare products for animals. The Company provides wellness and anti-aging products, aesthetic innovation products, companion animal health products and livestock products. Its products include PREBO, YUUU toothpaste, multivitamin, Probac 7, Probac 10, Beta Glucan Plus, Pure Krill Oil, Astacurmin, YUUU cleansing mousse, Perfectha Complement, Perfectha Derm, Perfectha Deep, Perfectha Subskin and Uderma.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	3.21B 94.85M 83.42M 77.49M 71.27M 134M 9.18B 136M 927M 361M 4.48B 356M 348M 15.54B	P/E 2024	52.3x	P/E 2025	22.8x
Enterprise Value	3.33B 98.37M 86.52M 80.37M 73.92M 139M 9.53B 141M 961M 375M 4.65B 369M 361M 16.12B	EV / Sales 2024	1.13x	EV / Sales 2025	1.31x
Free-Float	-	Yield 2024 *	-	Yield 2025	1.59%

05-11	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-02	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-01	Inter Pharma Public Company Limited announces Annual dividend, payable on May 25, 2026	CI
11-11	Inter Pharma Public Company Limited (SET:IP) agreed to acquire an additional 49% stake in Interpharma- ZEAvita Company Limited from Thai Union Ingredients.	CI
11-11	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	Inter Pharma Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-13	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-16	Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal	MT
25-04-16	Zhaoke Ophthalmology Limited Enters into Three Distribution and Supply Agreements with Interpharma Public Company Limited	CI
25-04-01	Inter Pharma Public Company Limited Signs Exclusive Distribution Agreement with Zhaoke Ophthalmology Company Limited for Comprehensive Eye Care Innovation	CI
25-02-25	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-25	Inter Pharma Public Company Limited Proposes to Omit Dividend Payment for the Year Ended December 31, 2024	CI
24-11-13	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

22-08-16	Inter Pharma : New shares of IP to be traded on August 18, 2022	PU
22-08-10	Inter Pharma Public : Notification on Change of Directors and Authorization of Directors	PU
22-08-10	Inter Pharma Public : Report on the results of sale of common shares offered to private placement (F53-5)	PU
22-08-10	Inter Pharma Public : Right Adjustment of IP-W1 (Edited)	PU
22-08-09	Inter Pharma Public : Right Adjustment of IP-W1	PU

Manager	Title	Age	Since
Trinnawat Thanitnithiphan CEO	Chief Executive Officer	56	2014-01-31
Chatkaew Krudkosol DFI	Director of Finance/CFO	56	2023-06-22
Chompunuch Meevang CMP	Compliance Officer	54	-

Director	Title	Age	Since
Napaporn Dechakarat BRD	Director/Board Member	51	2017-06-13
Sansanee Chaiyaroj BRD	Director/Board Member	64	2020-07-31
Trinnawat Thanitnithiphan BRD	Director/Board Member	56	2014-01-31

Inter Pharma Stock OTC Markets

Stocks

IPTB.F

TH9474010005

Pharmaceuticals

Valuation: Inter Pharma

Latest news : Inter Pharma

Press Releases: Inter Pharma

Managers and Directors: Inter Pharma

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTER PHARMA	-.--%	-.--%	-	-	92.33M
ELI LILLY AND COMPANY	+1.97%	+1.43%	+48.44%	+156.66%	1,037B
JOHNSON & JOHNSON	+1.42%	+3.72%	+53.32%	+52.34%	615B
ABBVIE INC.	+1.43%	+0.99%	+34.83%	+78.74%	448B
ROCHE HOLDING AG	+5.14%	+5.40%	+33.75%	+27.28%	326B
NOVARTIS AG	+1.85%	+3.57%	+37.09%	+39.87%	293B
ASTRAZENECA PLC	-0.11%	+0.48%	+18.87%	+17.81%	264B
NOVO NORDISK A/S	+0.25%	-4.62%	-27.66%	-42.25%	216B
AMGEN INC.	+1.49%	-0.02%	+20.14%	+58.21%	198B
GILEAD SCIENCES, INC.	+0.40%	-3.99%	+15.23%	+62.28%	162B
Average	+1.38%	+0.30%	+26.00%	+50.10%	395.27B
Weighted average by Cap.	+1.73%	+1.12%	+35.40%	+75.23%

	2024	2025
Net sales	1.91B 56.52M 49.71M 46.18M 42.47M 79.65M 5.47B 81.08M 552M 215M 2.67B 212M 208M 9.26B	2.21B 65.45M 57.57M 53.48M 49.18M 92.24M 6.34B 93.89M 639M 249M 3.09B 246M 240M 10.73B
Net income	37.28M 1.1M 969K 900K 828K 1.55M 107M 1.58M 10.77M 4.2M 52.05M 4.14M 4.05M 181M	122M 3.62M 3.18M 2.96M 2.72M 5.1M 350M 5.19M 35.35M 13.79M 171M 13.58M 13.29M 593M
Net Debt	209M 6.18M 5.43M 5.05M 4.64M 8.7M 598M 8.86M 60.34M 23.54M 292M 23.19M 22.68M 1.01B	119M 3.53M 3.1M 2.88M 2.65M 4.97M 342M 5.06M 34.46M 13.44M 167M 13.24M 12.95M 578M